Table 1.
Characteristics of the included studies.
| Study, Year | Gene | Variant | Association? | OR (95% CI) |
p value |
|
|---|---|---|---|---|---|---|
| Wanvisa et al., 2019 | Adiponectin | rs1501299 G/T | Over-representation of the GG genotype and G allele in the injury group | 1.91(1.04–3.53) 1.89(1.19–3.01) |
0.026 0.004 |
|
| Lulińska-Kuklik et al., 2019 | MMP3 MMP8 TIMP2 |
rs591058 C/T rs679620 G/A rs11225395C/T rs4789932 G/A |
Over-represented rs679620 G and rs591058C alleles of MMP in the injury group |
1.38(1.05–1.81) |
0.021 |
|
| Lulińska-Kuklik et al., 2020 | MMP1 MMP10 MMP12 |
rs1799750 -/G rs486055 C/T rs2276109 T/C |
No association | |||
| Gibbon et al., 2017 | MMP3 | rs679620 A/G rs591058 T/C rs650108 G/A rs3025058 C/G |
No association | |||
| Lulińska-Kuklik et al., 2018 | COL5A1 | rs12722 C/T rs13946 C/T |
Under-representation of the CT genotype of rs13946 in the injury group | Not shown | 0.039 | |
| Shukla et al., 2020 | COL1A1 | rs1800012 G /T | No association | |||
| Zhao et al., 2020 | COL1A1 COL5A1 COL12A1 B-fibrinogen |
rs1800012 G/T rs12722 C/T rs13946 C/T rs970547 A/G rs240736 C/T rs1800787 C/T rs1800788 C/T rs1800789 A/G rs1800790 A/G rs1800791 A/G rs2227389 C/T |
Under-representation of the TT genotype of B-fib rs1800787 in the injury group; over-representation of rs1800788 CT, rs1800790 AG, and rs2227389 CT in the injury group; over-representation of the rs970547 A allele and AA genotype in the male injury group. |
For rs970547 1.80 (A) 1.61 (AA |
<0.05 0.019(A) 0.026(AA) |
|
| Laguette et al., 2020 | COL5A1 TGFBR3 TGFBIT |
rs3922912 G/A rs4841926 C/T rs3124299 C/T rs1805113 G/A rs1805117 T/C rs1442 G/C |
TGFBR3 rs1805113 AA vs. GG TGFBI rs1442 CC vs GG |
0.3(0.11–0.80) 0.3(0.12–0.77) |
0.017 0.013 |
|
| Gibbon et al., 2020 | COL1A1 |
rs1107946 G/T rs1800012 G/T |
No association | |||
| Perini et al., 2022 | COL1A1 COL1A2 |
rs1107946 G/T rs412777 A/C rs42524 C/G rs2621215 G/T |
COL1A2 SNPs (rs42524 CC and rs2621215 GG) were associated with an increased risk of non-contact ACL injury | 5.73(1.22–26.95) 4.29(1.26–14.61) |
Not shown Not shown |
|
| Sivertsen et al., 2019 | COL1A1 COL3A1 COL5A1 COL12A1 |
rs1800012 A/C rs1107946 A/C rs1800255 A/G rs12722 C/T rs13946 C/T rs970547 C/T |
No association |
|||
| Suijkerbuijk et al., 2019 | COL5A1 IL1B IL6 IL6R |
rs12722 C/T rs16944 C/T rs1800795 G/C rs2228145 G/C |
Over-representation of the IL6R rs2228145 CC genotype in the SA-control group |
Not shown |
0.028 |
|
| Lulińska-Kuklik et al., 2019 | VEGFA | rs699947 A/C rs1570360 A/G rs2010963 C/G |
Over-representation of the VEGFA rs2010963 CC genotype in the injury group |
1.85(1.11–3.08) |
0.047 |
|
| Lulinska-Kuklik et al., 2019 |
IL1B IL6 IL6R |
rs16944 G/A rs1143627 G/A rs1800795 C/G rs2228145 C/A |
The rs1800795 IL6 gene polymorphism was associated with the ACL rupture | 1.74(1.08–2.81) |
0.010 Codominant 0.022 Recessive 0.004 Overdominant |
|
| Rahim et al., 2022 | IL1B IL6 IL6R VEGFA KDR |
rs16944 C/T rs1800795 G/C rs2228145 C/A rs699947 C/A rs1570360 G/A rs2010963 C/G rs2071559 A/G rs1870377 T/A |
Over-representation of the VEGFA rs2010963 GC and CC genotype of rs699947 in the injury group |
2.43(1.00–5.87) 3.35(1.17–9.62) |
0.049 0.024 |
|
| Rahim et al., 2022 | IL1B IL6 IL6R VEGFA KDR |
rs16944 C/T rs1800795 G/C rs2228145 C/A rs699947 C/A rs1570360 G/A rs2010963 C/G rs2071559 A/G rs1870377 T/A |
Over-representation of the VEGFA rs2010963 GC and CC genotype of rs699947 in the injury group |
2.43(1.00–5.87) 3.35(1.17–9.62) |
0.049 0.024 |
|
| Rahim et al., 2017 | IL1B IL6 IL6R CASP8 TNF TNFRSF1B PTGER4 TGFB2 |
rs16944 C/T rs1800795 G/C rs2228145 G/C rs3834129 ins/del rs1045485 C/G rs1799964 C/T rs1800629 A/G rs1061622 G/T rs4495224 A/C rs7550232 A/C |
Under-representation of the IL1B rs16944 TT genotype in the female control group; over-representation of the CASP8 rs3834129 ins allele in the control group. |
3.06(1.09–8.64) 1.46(1.01–2.12) |
0.039 0.047 |
|
| Feldmann et al., 2022 | VEGFA KDR |
rs699947 C/A rs1570360 G/A rs2010963 G/C rs2071559 G/A rs1870377 T/A |
Under-representation of the VEGFA rs2010963 GG genotype in the SWE ACL group; Under-representation of the VEGFA AAG haplotype in the combined ACL |
2.8(1.45–5.41) 0.85(0.69–1.05) |
0.001 0.010 |
|
| Seale et al., 2020 | CASP8 | rs3834129 ins/Del rs1045485 G/C rs13113 T/A |
No association | |||
| Lulińska-Kuklik et al., 2019a | TNC | rs1330363 C/T rs2104772 T/A rs13321 G/C |
No association | |||
| Gibbon et al., 2018 | TNC COL27A1 |
rs1061494 C/T rs1138545 C/T rs2104772 A/T rs1061495 C/T rs2567706 A/G rs2241671 A/G rs2567705 A/T |
Under-representation of the TNC rs2104772 AA genotype in the female control group | 2.3(1.1–5.5) | 0.035 | |
| Willard et al., 2018 | BGN DCN COL5A1 |
rs1126499 C/T rs1042103 G/A rs516115 C/T rs12722 C/T |
Allele combinations across BGN, COL5A1 and DCN in modulating susceptibility to ACL injury |
|||
| Ciȩszczyk et al., 2017 | ACAN BGN DCN VEGFA |
rs1516797 G/T rs1042103 A/G rs1126499 C/T rs516115 C/T rs699947 A/C |
Under-representation of the ACAN rs1516797 G/T genotype in the control group; under-representation of the BGN rs1042103 A allele in the male control group |
1.68(1.09–2.57) 1.5(1.05–2.15) |
0.017 0.029 |
|